In vitro and ex vivo assays for drug targeting obesity/type 2 diabetes and NASH/MASH
To limit the use of animals and support our customers combatting obesity/type 2 diabetes and NASH/MASH.
Physiogenex offers its experience/expertise and a panel of in vitro and ex vivo services.
Optimize and expedite your preclinical drug development programs with our validated systems of adipocytes (human and rodent), muscle (rodent), hepatocyte steatosis model (HepaRG, monolayer), 3D NASH model (human hepatocytes, Kupffer cells and Stellate cells in spheroids culture).
Our validated in vitro and ex vivo assays
Preclinical CRO Services for obesity, insulin resistance and diabetes
In vivo drug efficacy experiments
- Muscles/adipocytes ex vivo glucose uptake
- Muscles/adipocytes ex vivo FFA oxydation
- Adipocytes ex vivo lipolysis
In vivo drug efficacy experiments
Glucose homeostasis
- Glucose and insulin tolerance test
- Hyperinsulinemic euglycemic/hyperglycemic clamps with 3H-glucose (hepatic glucose production, turnover, glycolysis, etc.) and 14C-2-deoxyglucose (glucose uptake)
- In vivo individual tissue glucose uptake
Lipid metabolism
- Lipid tolerance test
- Lipogenesis in vivo with 3H2O or 14C-acetate
In vivo services
- Body weight food/water intake, organs collection, weight and fixation (fat pads, liver, etc.), blood collection and tissue dissection
- Cardiometabolic parameters (echocardiography)
- Indirect calorimetry (energy expenditure), Echo MRI (body composition)
Biochemistry assays and histology
- Standard hormones (insulin, glucagon, adiponectin, leptin, etc.)
- Inflammation (plasma cytokines)
- Tissue analysis (lipids, gene and protein expression)
- Histology, immunohistology and histopathological scoring
biochemical assays and histology analysis
Our major scientific publications on obesity, insulin resistance and diabetes:
CONTACT US FOR MORE INFORMATION